DOCS Stock Overview
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
Dr. Martens plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.78 |
52 Week High | UK£1.75 |
52 Week Low | UK£0.62 |
Beta | 0.0078 |
1 Month Change | -17.56% |
3 Month Change | -7.60% |
1 Year Change | -52.57% |
3 Year Change | -82.85% |
5 Year Change | n/a |
Change since IPO | -82.58% |
Recent News & Updates
Recent updates
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
Mar 27Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet
Mar 06Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price
Feb 08Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market
Jan 21Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156
Jan 03Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156
Dec 13Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation
Oct 12Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Sep 13Returns on Capital Paint A Bright Future For Dr. Martens (LON:DOCS)
Jul 12A Look At The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Jun 02Dr. Martens (LON:DOCS) Is Investing Its Capital With Increasing Efficiency
Feb 25Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 34% Undervaluation?
Dec 17The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
Oct 02Dr. Martens (LON:DOCS) Knows How To Allocate Capital Effectively
Jul 04Why Investors Shouldn't Be Surprised By Dr. Martens plc's (LON:DOCS) 26% Share Price Surge
Jun 16Are Investors Undervaluing Dr. Martens plc (LON:DOCS) By 27%?
Mar 02Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 19% Below Its Share Price
Dec 01Are Dr. Martens plc (LON:DOCS) Investors Paying Above The Intrinsic Value?
Aug 24Investors Can Find Comfort In Dr. Martens' (LON:DOCS) Earnings Quality
Jun 24Does This Valuation Of Dr. Martens plc (LON:DOCS) Imply Investors Are Overpaying?
Apr 29Shareholder Returns
DOCS | GB Luxury | GB Market | |
---|---|---|---|
7D | -3.1% | 1.4% | 2.3% |
1Y | -52.6% | -46.9% | 5.6% |
Return vs Industry: DOCS underperformed the UK Luxury industry which returned -47% over the past year.
Return vs Market: DOCS underperformed the UK Market which returned 5.2% over the past year.
Price Volatility
DOCS volatility | |
---|---|
DOCS Average Weekly Movement | 10.1% |
Luxury Industry Average Movement | 5.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: DOCS has not had significant price volatility in the past 3 months.
Volatility Over Time: DOCS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1945 | 2,591 | Kenny Wilson | www.drmartensplc.com |
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name.
Dr. Martens plc Fundamentals Summary
DOCS fundamental statistics | |
---|---|
Market cap | UK£754.16m |
Earnings (TTM) | UK£103.20m |
Revenue (TTM) | UK£977.50m |
7.3x
P/E Ratio0.8x
P/S RatioIs DOCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DOCS income statement (TTM) | |
---|---|
Revenue | UK£977.50m |
Cost of Revenue | UK£362.30m |
Gross Profit | UK£615.20m |
Other Expenses | UK£512.00m |
Earnings | UK£103.20m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 30, 2024
Earnings per share (EPS) | 0.11 |
Gross Margin | 62.94% |
Net Profit Margin | 10.56% |
Debt/Equity Ratio | 86.5% |
How did DOCS perform over the long term?
See historical performance and comparison